Pharmaceutical

Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric patients.

Oct 24, 2024 - 04:00
Health Canada approves Servier’s VORANIGO for IDH-mutant glioma
Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric patients.
Read the original article

Tags:

Previous Article

AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD

Next Article

A slow start for self-amplifying mRNA vaccines

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Q&A: Solving astronauts’ health challenges in deep space could have payoffs on Earth

Q&A: Solving astronauts’ health challenges in deep spac...

Feb 17, 2024

Astellas invests $50m in Poseida’s CAR-T cell therapy

Astellas invests $50m in Poseida’s CAR-T cell therapy

Aug 8, 2023

BGB-30813 by BeiGene for Head And Neck Squamous Cell Ca...

Dec 26, 2023